Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
Calviño C, Ceballos C, Alfonso A, Jauregui P, Calleja-Cervantes ME, San Martin-Uriz P, Rodriguez-Marquez P, Martin-Mallo A, Iglesias E, Abizanda G, Rodriguez-Diaz S, Martinez-Turrillas R, Illarramendi J, Viguria MC, Redondo M, Rifon J, Villar S, Lasarte JJ, Inoges S, Lopez-Diaz de Cerio A, Hernaez M, Prosper F, Rodriguez-Madoz JR. Calviño C, et al. Among authors: inoges s. Front Immunol. 2023 Sep 19;14:1270843. doi: 10.3389/fimmu.2023.1270843. eCollection 2023. Front Immunol. 2023. PMID: 37795087 Free PMC article.
Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
González I, Andreu EJ, Panizo A, Inogés S, Fontalba A, Fernández-Luna JL, Gaboli M, Sierrasesúmaga L, Martín-Algarra S, Pardo J, Prósper F, de Alava E. González I, et al. Among authors: inoges s. Clin Cancer Res. 2004 Jan 15;10(2):751-61. doi: 10.1158/1078-0432.ccr-0778-03. Clin Cancer Res. 2004. PMID: 14760098 Free article.
[Past, present and future of anti-idiotype vaccination].
Rodríguez Calvillo M, Inogés S, López Díaz de Cerio A, Zabalegui N, Panizo C, Hernández M, Pérez Calvo J, Prósper F, Melero I, Sánchez-Ibarrola A, Rocha E, Bendandi M. Rodríguez Calvillo M, et al. Among authors: inoges s. Rev Med Univ Navarra. 2004 Jul-Sep;48(3):14-23. Rev Med Univ Navarra. 2004. PMID: 15622921 Review. Spanish.
Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A. Bendandi M, et al. Among authors: inoges s. Leuk Lymphoma. 2006 Jan;47(1):29-37. doi: 10.1080/10428190500272473. Leuk Lymphoma. 2006. PMID: 16321824 Clinical Trial.
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis.
Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P. Martinez-Forero I, et al. Among authors: inoges s. Eur J Immunol. 2008 Feb;38(2):576-86. doi: 10.1002/eji.200737271. Eur J Immunol. 2008. PMID: 18200504 Free article.
Prolonged idiotypic vaccination against follicular lymphoma.
Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M. Inoges S, et al. Leuk Lymphoma. 2009 Jan;50(1):47-53. doi: 10.1080/10428190802601122. Leuk Lymphoma. 2009. PMID: 19152172 Free article.
74 results